This place is so inept it’s embarrassing to watch.
Biogen loses another bid to revive Tecfidera patent as generic keeps eating into blockbuster sales – Endpoints News
Endpoints News
When Biogen lost its appeal to revive a key patent for Tecfidera last November, the big biotech filed for a rehearing in a last-ditch effort to restore its crumbling blockbuster multiple sclerosis franchise.
Four months later, the appeals court has rejected its request.
Appeals court puts the final nail in the coffin for Tecfidera patent, adding to Biogen's burgeoning setbacks
The setback leaves the Supreme Court as Biogen’s final resort if it still wants to block Viatris — formerly Mylan — from marketing a Tecfidera generic, which has and is expected to seriously eat into Tecfidera sales.
Although it may come as little surprise, the legal defeat puts another nail in the coffin at a desperate time for Biogen, whose CEO Michel Vounatsos is keeping his hands on the axe.
Biogen loses another bid to revive Tecfidera patent as generic keeps eating into blockbuster sales – Endpoints News
Endpoints News
When Biogen lost its appeal to revive a key patent for Tecfidera last November, the big biotech filed for a rehearing in a last-ditch effort to restore its crumbling blockbuster multiple sclerosis franchise.
Four months later, the appeals court has rejected its request.
Appeals court puts the final nail in the coffin for Tecfidera patent, adding to Biogen's burgeoning setbacks
The setback leaves the Supreme Court as Biogen’s final resort if it still wants to block Viatris — formerly Mylan — from marketing a Tecfidera generic, which has and is expected to seriously eat into Tecfidera sales.
Although it may come as little surprise, the legal defeat puts another nail in the coffin at a desperate time for Biogen, whose CEO Michel Vounatsos is keeping his hands on the axe.